{
  "docId": "019de074-0cc8-70d5-8924-3a1b552a09af",
  "docSlug": "77b0d3b8437e31981ed49d98afb5005f",
  "documentTitle": "OmniAb | Investor Conference Presentation Deck | 43 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 43,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "other",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Slide 42 of a presentation deck.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de074-0cc8-70d5-8924-3a1b552a09af/42",
  "deckHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af",
  "deckJsonHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af.json",
  "deckAnchorHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.8,
        "y": 0.02
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8839aaec-e712-4a60-b6d9-8b15a310484d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "list",
      "text": "Sugemalimab (Cejemly®) was approved in China in June of 2022 for unresectable stage III non-small cell lung cancer (NSCLC) following concurrent or sequential chemoradiotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a23bd17-a57b-4e80-befd-86d555794ccf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.04,
        "y": 0.67
      },
      "kind": "list",
      "text": "EQRx licensed exclusive rights to sugemalimab for development / commercialization outside of China, targeting first regulatory filings ex-US in 2H 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62086a67-e87d-49a1-8eea-e4497b5c1cca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.04,
        "y": 0.6
      },
      "kind": "list",
      "text": "Pfizer responsible for commercializing in China via 2020 strategic collaboration with CStone",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "971adaca-0e53-4175-8b18-95cf438624c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "Fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) mAb, which may reduce risk of immunogenicity and toxicity, a unique advantage over similar drugs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afe7a85f-e628-4689-be77-534375904696",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.4
      },
      "kind": "list",
      "text": "Previously approved in China in December 2021, and launched in January 2022, for first-line treatment of metastatic non-squamous NSCLC in combination with chemotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d206119f-c63d-4a3b-ab97-19a0a7ae38d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.5
      },
      "kind": "list",
      "text": "Becomes first anti-PD-1/PD-L1 mAb approved for stage III NSCLC, and is also the only one approved for both stage III and stage IV NSCLC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7e003fa-0330-436e-acd7-751ba35cd424",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Sugemalimab",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "244bcfb1-607a-473e-92d6-c6f686434a46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "title",
      "text": "THE SECOND APPROVED OMNIRAT-DERIVED ANTIBODY",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02753d62-c81f-4eef-8893-f0fb48d2026d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}